Gaithersburg, MD, May 19, 2015 – MaxCyte® Inc., the pioneer in cell therapies using scalable, highperformance cell transfection systems, announced today that MaxCyte and its collaborators will present data from selected applications on how modulation of biological activity leads to development and delivery of “enhanced” potency immune cell therapies. The presentations will take place during a tutorial sponsored by MaxCyte at the Annual Meeting of the International Society of Cellular Therapies (ISCT).
The tutorial, entitled “Rapid, Automated, Scalable, cGMP-compliant Non-viral Platform for Enabling Development of ‘Enhanced’ Potency Cell Therapy Products,” will highlight the use of the MaxCyte GT® Flow Transfection System in developing enhanced potency stem cell, T-cell, and NK-cell products. In the tutorial, data will be presented on selected applications that demonstrate how modulation of multiple biological pathways leads to development and delivery of pharmaceutically engineered products with augmented biological activity.
“We are especially excited to have our collaborators discuss their research in augmenting and enhancing biological activity of immune cell using messenger RNA-based electroporation, without any toxicity to physiology or function of the cells, and translating these into clinically relevant scale for patient treatments,” stated Dr. Peshwa. “We look forward to continuing to build on additional collaborations with major academic translation centers and assist them in rapid translation to clinic of non-virally engineered cell therapies that may potential results in improved clinical benefits.”
Details of the MaxCyte-sponsored tutorial are as follows:
Event: Rapid, Automated, Scalable, cGMP-compliant Non-viral Platform for Enabling Development of ‘Enhanced’ Potency Cell Therapy Products
Date: May 28, 2015
Time: 12:45-1:45 PM
Location: Pompeian III/IV, ISCT, Caesars Palace Hotel and Convention Center, 3570 S. Las Vegas Blvd., Las Vegas, Nevada
MaxCyte is a world leader in the discovery, development, manufacture, and delivery of innovative cell-based medicines utilizing its novel best in class cell modification technology.
MaxCyte has developed a next-generation technology–MaxCyte GT® Flow Transfection System–for the rapid engineering of human cells as therapeutics, enabling the development of safer, more effective and lower cost cell-based therapies for a broad range of applications with blockbuster commercial potential. The company currently has clinical, pre-clinical-partnered, and proprietary products under development and is involved in more than a dozen clinical trials.
MaxCyte’s proprietary CARMA products utilize a universal platform for the rapid, automated loading of messenger RNA, encoding for Chimeric Antigen Receptors (CARs), into peripheral blood cells without the need for ex vivo expansion, reducing time, cost, and complexity associated with centralized manufacturing for ex vivo cell expansion-based processes. The loading of fresh patient cells with CAR mRNA harnesses immune cells for targeted killing of tumors. This anti-tumor activity is not dependent on the patient’s immune system and is independent of cell surface concentration of the tumor antigen. MaxCyte recently entered into a collaboration with The Johns Hopkins Kimmel Cancer Center to treat solid tumors with its CARMA products.
The Company also markets a portfolio of products and services that include the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System. These platforms are used in drug discovery research and screening and protein production by 9 of the top 10 pharma companies worldwide as well as the top three in Japan. MaxCyte products enable the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
For more information visit /